Donate Now Become a member

Cart (0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

DIA Global Center

Sep 11, 2017 8:15 AM - Sep 12, 2017 3:30 PM

21 Dupont Circle NW, Suite 300, Washington, DC 20036

Navigating Chemistry, Manufacturing, and Controls Through the Drug Development Process

Back to Agenda

Session 5: CMC Requirements for an IND

Session Chair(s)

Albert S. Yehaskel, MBA

Albert S. Yehaskel, MBA

President and CEO

Refuah Global Pharmaceutical Development, Inc., United States

Part A: Drug Substance

Part A of the IND will discuss in detail how to design the Drug Substance portion of an IND with real examples

Part B: Drug Product

Part B of the IND will discuss in detail how to design the Drug Product portion of an IND with real examples

Part C: Placebo

Part C of the IND will discuss in detail how to design the Placebo portion of an IND in the event placebos are used in clinical trials

Have an account?